VYNE Therapeutics Inc. (VYNE)

VYNE Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	24.63	24.03	19.93	30.67	30.98	42.86
Short-Term Investments	0.3	4.98	41.59	62.63	-	-
Cash & Short-Term Investments	24.93	29.01	61.52	93.31	30.98	42.86
Cash Growth	-50.41%	-52.84%	-34.07%	201.23%	-27.72%	-27.91%
Accounts Receivable	-	-	-	-	-	7.58
Other Receivables	-	-	-	-	5	-
Total Trade Receivables	-	-	-	-	5	7.58
Other Current Assets	0.86	1	2.92	2.66	2.3	12.75
Total Current Assets	25.79	30.01	64.44	95.96	38.28	63.19
Net Property, Plant & Equipment	0.08	0.09	0.21	0.21	-	0.35
Other Long-Term Assets	-	0.06	2.26	1.52	2.48	3.51
Total Assets	25.87	30.16	66.91	97.69	40.76	67.05

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	0.26	1.04	2.71	1.66	2.39	6.51
Accrued Expenses	0.98	1.35	10.7	5.76	6.96	11.55
Current Portion of Leases	-	-	0.1	0.12	-	0.35
Other Current Liabilities	-	-	1.31	-	-	-
Total Current Liabilities	1.24	2.4	14.82	7.54	9.35	18.41
Long-Term Leases	-	-	-	0.1	-	-
Other Long-Term Liabilities	-	-	-	1.31	-	-
Total Long-Term Liabilities	-	-	-	1.41	-	-
Total Liabilities	1.24	2.4	14.82	8.95	9.35	18.41

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0	0	0	0	0	0.01
Additional Paid-in Capital	785.87	785.41	783.24	780.04	693.94	688.16
Accumulated Other Comprehensive Income	-	0	0.02	0.03	-	-
Retained Earnings	-761.24	-757.65	-731.17	-691.34	-662.74	-639.53
Total Common Shareholders' Equity	24.64	27.77	52.09	88.74	31.2	48.64
Minority Interest	-	-	-	-	0.21	-
Shareholders' Equity	24.64	27.77	52.09	88.74	31.41	48.64
Total Liabilities & Equity	25.87	30.16	66.91	97.69	40.76	67.05

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	-	0	0.1	0.21	0	0.35
Net Cash (Debt)	24.93	29.01	61.42	93.09	30.98	42.51
Net Cash Growth	-50.35%	-52.77%	-34.03%	200.54%	-27.13%	72.36%
Net Cash Per Share	37.37	43.52	72.10	453.10	486.11	743.37
Book Value	24.64	27.77	52.09	88.74	31.2	48.64
Book Value Per Share	36.93	41.66	61.15	431.88	489.69	850.58
Tangible Book Value	24.64	27.77	52.09	88.74	31.2	48.64
Tangible Book Value Per Share	36.93	41.66	61.15	431.88	489.69	850.58

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: May 15, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error